BioCatalyst

CFI-402257, Fulvestrant — catalyst calendar

1 verified catalyst event(s) referencing CFI-402257, Fulvestrant, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08 (month)
in 1mo
ESTIMATED
 READOUT
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulve
Phase 1/2 · Advanced Solid Tumor, Breast Cancer
 Treadwell Therapeutics, Inc CFI-402257, Fulvestrant ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.